Although neurofilament light chain (Nf-L) is not specific to multiple sclerosis (MS) and is elevated in other neurological conditions, it remains the most investigating and promising biomarker for detecting axonal damage in MS and plays a definitive role in predicting disease progression [17,18]. Here, NEFL is linked to myeloid sarcoma.